1. Home
  2. GTHX

GTHX

G1 Therapeutics Inc.

Logo G1 Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine and enhance the anti-tumor activity of current therapies. Its product COSELA indicates to help protect bone marrow from the damage of chemotherapy.

Founded: 2008 Country:
United States
United States
Employees: N/A City: RESEARCH TRIANGLE PARK
Market Cap: 214.5M IPO Year: 2017
Target Price: $10.80 AVG Volume (30 days): 1.3M
Analyst Decision: Buy Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.93 EPS Growth: N/A
52 Week Low/High: $1.08 - $5.00 Next Earning Date: 05-01-2024
Revenue: $82,511,000 Revenue Growth: 60.84%
Revenue Growth (this year): -13.63% Revenue Growth (next year): 48.10%

Share on Social Networks: